The prognosis is generally poor. The RS score<unk>  syndrome score), which is an estimate of the patient's prognosis, is based on the patient's performance status, LDH, platelet count, the size of the lymphoma tumors, and the number of prior therapies already received. Overall, the median survival is between five and eight months. Untreated, RS is invariably fatal. The Hodgkin's lymphoma variant of<unk> 's carries a better prognosis than the predominant diffuse large B-cell lymphoma type, but a worse prognosis than a de novo case of Hodgkin's.
Richter's transformation
Lupus nephritis
Shunt nephritis
Phosphate nephropathy
Benign nephrosclerosis
Analgesic nephropathy
IgA nephropathy
Myeloma cast nephropathy